Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Thomas McCormick

Adolescent Medicine Louisville, KY Medical Doctor

NPI 1295720506 CMS profile 285014

9905 Shelbyville Rd, Louisville, KY 40223

Open in the dashboard

General payments

$2,728

215 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Thomas McCormick of Louisville, KY is reported in the CMS Open Payments database as having received $2,728 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $621 48
2022 General $686 56
2021 General $794 65
2020 General $292 24
2019 General $335 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas McCormick
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Thomas McCormick were reported at $0. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year Thomas McCormick Adolescent Medicine median Middle half National median
2019 $335 $95 $36–$198 $163
2020 $292 $50 $23–$111 $114
2021 $794 $67 $27–$179 $132
2022 $686 $79 $29–$189 $149
2023 $621 $100 $39–$194 $160
2024 $0 $93 $38–$195 $164
2025 $0 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Supernus Pharmaceuticals, Inc. $510 76 payments
  2. Corium, Inc. $396 22 payments
  3. Tris Pharma Inc $369 22 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $339 17 payments
  5. Neos Therapeutics, LP $237 22 payments
  6. Ironshore Pharmaceuticals Inc. $130 8 payments
  7. Sanofi Pasteur Inc. $118 7 payments
  8. GlaxoSmithKline, LLC. $96 7 payments
  9. Adlon Therapeutics L.P. $81 6 payments
  10. Merck Sharp & Dohme Corporation $71 4 payments
  11. Other $382 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,728 215 payments
Products named General payments · program years 2019–2023
  1. QELBREE $510 76 payments
  2. Azstarys $396 22 payments
  3. VYVANSE $359 18 payments
  4. Dyanavel XR Adhd $224 13 payments
  5. COTEMPLA XR-ODT $196 19 payments
  6. Adzenys XR-ODT $157 16 payments
  7. VAXELIS $118 7 payments
  8. BEXSERO $83 6 payments
  9. Dyanavel XR Adhd $82 5 payments
  10. PEDIARIX $82 6 payments
  11. Other $1,041 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record